PROTECTION OF NORMAL CELLS
    1.
    发明申请
    PROTECTION OF NORMAL CELLS 失效
    保护正常细胞

    公开(公告)号:US20090326073A1

    公开(公告)日:2009-12-31

    申请号:US12115331

    申请日:2008-05-05

    IPC分类号: A61K31/19 A61P43/00

    摘要: The invention provides compositions comprising sulindac, R-epimer sulindac, S-epimer sulindac, derivatives, metabolites, and structural analogs thereof which protect normal cells against damage caused by solar rays, oxidative damage, environmental factors, diseases and organisms.

    摘要翻译: 本发明提供包含舒林酸,R-差向异构体舒林酸,S-差向异构体舒林酸,其衍生物,代谢物及其结构类似物的组合物,其保护正常细胞免受由太阳光线,氧化损伤,环境因素,疾病和生物引起的损害。

    Protection of normal cells
    5.
    发明授权
    Protection of normal cells 失效
    保护正常细胞

    公开(公告)号:US08487128B2

    公开(公告)日:2013-07-16

    申请号:US12115331

    申请日:2008-05-05

    IPC分类号: C07C315/00

    摘要: The invention provides compositions comprising sulindac, R-epimer sulindac, S-epimer sulindac, derivatives, metabolites, and structural analogs thereof which protect normal cells against damage caused by solar rays, oxidative damage, environmental factors, diseases and organisms.

    摘要翻译: 本发明提供包含舒林酸,R-差向异构体舒林酸,S-差向异构体舒林酸,其衍生物,代谢物及其结构类似物的组合物,其保护正常细胞免受由太阳光线,氧化损伤,环境因素,疾病和生物引起的损害。

    Novel reductase
    9.
    发明授权
    Novel reductase 失效
    新型还原酶

    公开(公告)号:US4374928A

    公开(公告)日:1983-02-22

    申请号:US269150

    申请日:1981-06-01

    摘要: A novel reductase which is an enzyme that can catalyze the reduction of methionine sulfoxide resides in proteins is described. The enzyme has been found in E. coli, Euglena gracilis, Tetrahymena pyriformis, Hela cells, rat tissue and spinach. The enzyme has an estimated molecular weight of about 18,000-20,000. It can be used to restore biological activity to proteins inactivated by oxidation of methionine residues.

    摘要翻译: 描述了一种新颖的还原酶,其是可以催化甲硫氨酸亚砜的还原的酶,其存在于蛋白质中。 该酶已被发现于大肠杆菌,小龙眼,四膜虫,Hela细胞,大鼠组织和菠菜中。 该酶的估计分子量约为18,000-20,000。 它可用于将生物活性恢复为蛋氨酸残基氧化失活的蛋白质。

    Treatment or prevention of cancer and precancerous disorders
    10.
    发明授权
    Treatment or prevention of cancer and precancerous disorders 失效
    治疗或预防癌症和癌前期疾病

    公开(公告)号:US08357720B2

    公开(公告)日:2013-01-22

    申请号:US12557022

    申请日:2009-09-10

    IPC分类号: A61K31/255 A61K33/40

    摘要: The NSAID, sulindac and/or its metabolites and derivatives, in combination with an agent that generates or induces reactive oxygen species (ROS), significantly enhances the killing of abnormal cells but does not affect normal cells. This effect occurs at concentrations of each compound that individually have little or no activity directed against the abnormal cells.

    摘要翻译: NSAID,舒林酸和/或其代谢物和衍生物与产生或诱导活性氧(ROS)的药剂组合显着增强异常细胞的杀伤,但不影响正常细胞。 这种效应发生在各自对于异常细胞具有很少或没有活性的化合物的浓度。